CR-T1-T4 / Curogen Technology - LARVOL DELTA

CR-T1-T4, a tri-specific anti-inflammatory and anti-Th17 protein drug candidate for the treatment of hidradenitis suppurativa (EADV 2025) - "Comparative evaluations of monotherapy and combination therapy were performed with competing agents Bimekizumab and Adalimumab in an HS-mimicking environment using human PBMCs...Histopathological analysis and cytokine profiling post-treatment were used to confirm the efficacy of CR-T1-T4 compared to Bimekizumab, Etanercept, and et cetera... CR-T1-T4 is a tri-specific soluble receptor TRAP protein that targets three key cytokines associated with HS. Our data shows that CR-T1-T4 exhibits a very low ADA response and low infection risk compared to current monoclonal antibody therapies in ex vivo models, while also demonstrating superior neutralizing effects in both in vivo and ex vivo studies. As a tri-specific Fc-fusion protein, CR-T1-T4 may offer a highly effective treatment option for HS patients who do not respond to, or relapse after, existing single-target antibody therapies."

Trispecific • Dermatology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammation • Psoriasis • IL17A • TNFA